Deals channel feed – Endpoints News

Deals channel feed

Biogen opts into Denali Alzheimer's program targeting amyloid beta plaque

3 years ago

Astellas takes $435M+ writedown on Evrenzo, hearing loss candidate and T cell therapy deal

3 years ago

Novo Nordisk taps into Canadian biotech’s cell therapies for diabetes and obesity in deal worth up to $2.6B

3 years ago

SPAC led by Biogen chairman Papadopoulos can't find a deal and will liquidate

3 years ago

Bristol Myers, Foundation Medicine expand collaboration to ex-Turning Point cancer drug

3 years ago

Takeda joins forces with small private biotech for preclinical Alzheimer's research

3 years ago

Extended FTC review adds wrinkle to Sanofi's $2.9B Provention Bio buyout

3 years ago

Sobi renegotiates nirsevimab deals, to pay $81M for US royalties and axe AstraZeneca agreement

3 years ago

Facing Chapter 11, Clovis sells Rubraca rights to Swiss pharma for $70M

3 years ago

Quince Therapeutics sets up poison pill with 'anti-takeover effects' after investor buyout bid

3 years ago

Incyte links arms with tiny Biotheryx for protein degrader deal, targeting cancer

3 years ago

Ginkgo snaps up gene therapy vector assets from StrideBio

3 years ago

PureTech wants to buy back its weight loss pill spinout after lackluster SPAC

3 years ago

Proxygen and Merck strike license deal worth up to $2.55B for protein degradation

3 years ago

Scorpion scores $65M as it lines up a partner to take EGFR programs global

3 years ago

Ginkgo sells Zymergen lab to chemical and material manufacturer Solvay

3 years ago

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early

3 years ago

Ginkgo partners up with Sensible Biotechnologies to forge mRNA manufacturing platform

3 years ago

AstraZeneca inks deal with Japanese biotech JCR in CNS indication

3 years ago

Second time’s the charm? Cyclerion CEO tries again at buying biotech's assets

3 years ago

BioNTech delves into ADCs with $170M upfront weeks after Pfizer lines up Seagen

3 years ago

Sartorius to acquire French manufacturer for $2.6B+ in cell and gene therapy play

3 years ago

Galapagos sends some employees — and a research unit — off to drug discovery CRO as part of reorg

3 years ago

MPP recruits three generic manufacturers to expand use of ViiV's injectable PrEP drug

3 years ago

First page Previous page 38 39 404142 43 44 Next page Last page